Predict your next investment

Caris Life Sciences company logo
Corporation
HEALTHCARE | Biotechnology
carislifesciences.com

See what CB Insights has to offer

Founded Year

1996

Stage

Private Equity - II | Alive

Total Raised

$1.314B

Valuation

$0000 

Last Raised

$830M | 4 mos ago

About Caris Life Sciences

Caris Life Sciences is an Irving, Texas-based provider of molecular science that assess DNA, RNA and proteins to reveal a molecular blueprint that allows physicians and cancer patients to make precise and personalized treatment decisions.

Caris Life Sciences Headquarter Location

750 W John Carpenter Fwy Suite 800

Irving, Texas, 75039,

United States

866-771-8946

Latest Caris Life Sciences News

Dr. Milan Radovich, Ph.D., Joins Caris Life Sciences As Chief Precision Medicine Officer

Sep 21, 2021

Dr. Milan Radovich, Ph.D., Joins Caris Life Sciences As Chief Precision Medicine Officer Radovich to oversee Caris' biomarker and drug intelligence teams, bringing over 10 years of clinical and academic experience to the Company Author: Sep 21, 2021 6:30 AM EDT IRVING, Texas, Sept. 21, 2021 /PRNewswire/ --  Caris Life Sciences ®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that Milan Radovich, Ph.D., has joined Caris as the Company's Chief Precision Medicine Officer. In this role, Dr. Radovich will lead the biomarker and drug intelligence teams which support Caris' focus on data-driven scientific advancements in biomarker signatures, therapeutic recommendations, genomic medicine, target discovery and drug development. The team will utilize the extensive database of over 275,000 cases of combined clinical and molecular data (CODEai) to develop novel signatures and drug targets, identify patients with unmet needs and determine how best to treat them. He will partner with the artificial intelligence (AI) team to create novel algorithms that will improve patients' lives and advance precision medicine. "We are very excited to welcome Dr. Radovich to Caris," said David Spetzler , M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences. "His expertise in the use of cutting-edge genomics in translational oncology, and leadership experience using genomics to guide therapy for cancer patients will further advance our mission to provide physicians with the most comprehensive and innovative treatment options for cancer patients worldwide." "I am thrilled to join Caris at such an exciting time for the Company," said Dr. Radovich. "As precision oncology is changing the cancer care landscape, and molecular information is dramatically improving the lives of cancer patients through research, innovative treatments and novel drug discoveries, Caris is the leading innovator in this space impacting patient outcomes now and into the future." Dr. Radovich brings over 10 years of clinical and academic experience to Caris. Before joining Caris, Dr. Radovich was an associate professor at the Indiana University School of Medicine, vice president for Oncology Genomics at Indiana University Health, and co-director of the IU Health Precision Genomics Program, a clinical program dedicated to the integration of cutting-edge genomics for the care of metastatic cancer patients. As an NCI-funded investigator, his research expertise focused on the use of genomics in translational oncology, particularly on the use of genomics in clinical studies, genomically-informed drug combinations, circulating biomarkers for cancer detection, and creating novel bioinformatic pipelines for cancer genome analyses. Dr. Radovich's laboratory has long-standing expertise in the research of triple-negative breast cancer, thymic malignancies and cancer precision medicine. About Caris Life SciencesCaris Life Sciences ® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes, and MI Transcriptome™ whole transcriptome sequencing with 22,000 RNA genes along with cancer-related pathogens, bacteria, viruses and fungi analysis run on every patient provides the most comprehensive and clinically relevant DNA and RNA profiling available on the market. Caris is also advancing precision medicine with Caris Artificial Intelligence, combining its market leading service offering, Caris Molecular Intelligence ® with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations. Headquartered in Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit  CarisLifeSciences.com  or follow us on Twitter ( @CarisLS). Caris Life Sciences Media Contact: Ann ObeneyCaris Life Sciences aobeney@carisls.com 469-550-1589 View original content to download multimedia: https://www.prnewswire.com/news-releases/dr-milan-radovich-phd-joins-caris-life-sciences-as-chief-precision-medicine-officer-301381149.html SOURCE Caris Life Sciences

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Caris Life Sciences

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Caris Life Sciences in 1 CB Insights research brief, most recently on Aug 5, 2021.

Expert Collections containing Caris Life Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Caris Life Sciences is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

M

Medical Devices

7,627 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,025 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

U

Unicorns- Billion Dollar Startups

836 items

H

Health & Wellness Assessment

77 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

Caris Life Sciences Patents

Caris Life Sciences has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Clusters of differentiation
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/6/2018

3/9/2021

Monoclonal antibodies, Molecular biology, Clusters of differentiation, Immunology, Biotechnology

Grant

Application Date

3/6/2018

Grant Date

3/9/2021

Title

Related Topics

Monoclonal antibodies, Molecular biology, Clusters of differentiation, Immunology, Biotechnology

Status

Grant

Caris Life Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Caris Life Sciences Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.